Expression of CTLA-4 molecule in peripheral blood T lymphocytes from patients with systemic lupus erythematosus

被引:36
作者
Liu, MF
Liu, HS
Wang, CR
Lei, HY
机构
[1] Natl Cheng Kung Univ, Coll Med, Dept Internal Med, Sect Rheumatol & Immunol, Tainan 70101, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 70101, Taiwan
[3] Natl Taiwan Univ, Coll Med, Dept Internal Med, Sect Rheumatol & Immunol, Taipei, Taiwan
关键词
CTLA-4; T cells; systemic lupus erythematosus;
D O I
10.1023/A:1023226621966
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CTLA-4 is a cell surface molecule expressed on activated T cells that is suggested to deliver a negative signal for T cell activation. Since CTLA-4 might be a negative regulator of autoimmune diseases, we investigated its expression on T cells from 20 patients with systemic lupus erythematosus (SLE) by flow cytometric analysis and RT-PCR. We found that although CTLA-4 mRNA was readily detected in all patients and controls, only a very minor subset of T cells expressed detectable surface CTLA-4 molecules in both groups. But patients with SLE had significantly increased percentages of CTLA-4-positive T cells compared with normal controls, implying at least that there was no apparent defective expression of CTLA-4 molecule in human lupus. The kinetics of CTLA-4 expression on T cells stimulated in vitro with PMA plus ionomycin were similar in normal controls and patients with SLE. The expression of CTLA-4 molecules after stimulation increased gradually and peaked at 72 hr. However, the induction of CTLA-4 expression on patients' T cells appeared to be weaker than that of normal individuals. Whether this reflects impaired downregulation by CTLA-4 molecules in SLE patients needs to be clarified further.
引用
收藏
页码:392 / 398
页数:7
相关论文
共 31 条
[1]  
Alegre ML, 1996, J IMMUNOL, V157, P4762
[2]   CD28-B7 INTERACTIONS IN T-CELL ACTIVATION [J].
ALLISON, JP .
CURRENT OPINION IN IMMUNOLOGY, 1994, 6 (03) :414-419
[3]   A NEW MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY - CTLA-4 [J].
BRUNET, JF ;
DENIZOT, F ;
LUCIANI, MF ;
ROUXDOSSETO, M ;
SUZAN, M ;
MATTEI, MG ;
GOLSTEIN, P .
NATURE, 1987, 328 (6127) :267-270
[4]  
Chuang E, 1997, J IMMUNOL, V159, P144
[5]   CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus [J].
Donner, H ;
Rau, H ;
Walfish, PG ;
Braun, J ;
Siegmund, T ;
Finke, R ;
Herwig, J ;
Usadel, KH ;
Badenhoop, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (01) :143-146
[6]   Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients [J].
GarciaCozar, FJ ;
Molina, IJ ;
Cuadrado, MJ ;
Marubayashi, M ;
Pena, J ;
Santamaria, M .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 104 (01) :72-79
[7]   IMMUNE FUNCTION IN SYSTEMIC LUPUS-ERYTHEMATOSUS - IMPAIRMENT OF INVITRO T-CELL PROLIFERATION AND INVIVO ANTIBODY-RESPONSE TO EXOGENOUS ANTIGEN [J].
GOTTLIEB, AB ;
LAHITA, RG ;
CHIORAZZI, N ;
KUNKEL, HG .
JOURNAL OF CLINICAL INVESTIGATION, 1979, 63 (05) :885-892
[8]  
HARPER K, 1991, J IMMUNOL, V147, P1037
[9]   THE B7 AND CD28 RECEPTOR FAMILIES [J].
JUNE, CH ;
BLUESTONE, JA ;
NADLER, LM ;
THOMPSON, CB .
IMMUNOLOGY TODAY, 1994, 15 (07) :321-331
[10]   CTLA-4: A negative regulator of autoimmune disease [J].
Karandikar, NJ ;
Vanderlugt, CL ;
Walunas, TL ;
Miller, SD ;
Bluestone, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) :783-788